Trial of DN022150 Versus Chemotherapy in Previously Treated Advanced Pancreatic Cancer With KRAS G12D Mutation

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer | NEJM

Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial

A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug

Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer trial

A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug

Experimental pill daraxonrasib nearly doubles survival time in advanced pancreatic cancer patients

A novel experimental pill called daraxonrasib has shown promise in extending survival for patients with advanced pancreatic cancer. The drug

Experimental daraxonrasib pill extends survival for advanced pancreatic cancer patients, study finds

An experimental pill called daraxonrasib has shown promise in helping patients with advanced pancreatic cancer live longer. The drug blocks

Daily pill daraxonrasib doubles survival for metastatic pancreatic cancer patients with KRAS mutation

A new daily pill called daraxonrasib has been shown to double survival time for metastatic pancreatic cancer patients with a KRAS mutation.

Experimental pill daraxonrasib extends survival in advanced pancreatic cancer patients, study finds

Researchers reported that daraxonrasib, a novel experimental pill, helped patients with advanced pancreatic cancer live longer by blocking a